Meisel Maria Leonor, do Céu Costa Maria, Pena Angelina
INFARMED, I.P., National Authority of Medicines and Health Products, 1749-004, Lisbon, Portugal.
Ecotoxicology. 2009 Nov;18(8):1176-81. doi: 10.1007/s10646-009-0365-7. Epub 2009 Jul 10.
Current knowledge shows that residues of human medicinal products at trace quantities are widespread in aquatic systems. The sewage treatment plants are pointed out as the major source discharge of these compounds on the environment. In this context, it has been worldwide recognised that the environmental impact of medicinal products have to be evaluated, according to recent EU legislation and regulatory guidance. The strategy of the global risk assessment includes primarily a pre-screening based on the estimation of exposure concentrations of drugs in the wastewater. The present paper addresses the decision-maker frontier of the ecologically relevant endpoints. Risk management recommendation and reasonable and prudent alternatives are discussed to minimise the possible environmental impact.
目前的知识表明，痕量人类药品残留物在水生系统中广泛存在。污水处理厂被指出是这些化合物向环境排放的主要来源。在这种背景下，根据欧盟最近的立法和监管指南，药品对环境的影响必须进行评估这一点已得到全球认可。全球风险评估策略主要包括基于废水中药物暴露浓度估算的预筛选。本文探讨了生态相关终点的决策者前沿问题。讨论了风险管理建议以及合理和审慎的替代方案，以尽量减少可能的环境影响。
